SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (95)2/5/1997 10:05:00 PM
From: John Zwiener   of 1115
 
James, I think the problem is that we are both not very clear in our statements. Perhaps nucleotide analogs is more to your liking? These act as false building blocks for viral DNA and RNA. I tend to think of them as antisense on the nucleotide level, but I guess they are different in a sense. If you disagree, will you explain in an understandible fashion. I would like to understand your viewpoint if you have something worthwhile.

Anyway, I still think that nucleotide analogs (better?) will still have some delay in use in immunocompetent patients for herpes. I can't shake the feeling that these analogs could get incorporated in human DNA or RNA. Or maybe a new virus could be created and then it's DNA get incorporated in humans. Whatever.

If they are pursuing use in hiv patients, well there is plenty of grant money to pay for it , so why not? Heck, it might work. I had asked lidak about the agreement with BMY and they won't disclose the arrangements.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News